– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment 

– Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in ACH-specific supine length Z-score of +0.42 from baseline through Week 52

– Treatment with TransCon CNP was generally well tolerated, with no reports of injection site reactions over the 52-week treatment period

COPENHAGEN, Denmark, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced Week 52 data from the open-label sentinel cohort portion of the reACHin Trial (which preceded the now fully enrolled double-blinded portion of the trial) showing that treatment with once-weekly TransCon CNP (navepegritide) provided stabilization or improvement in foramen magnum stenosis (a skull bone narrowing that can lead to dangerous brain stem and spinal cord compression), as well as linear growth benefits, in infants with achondroplasia aged 0 to <2 years. The data were presented by Geneviève Baujat, M.D., clinical geneticist at Necker-Enfants Malades Hospital (Paris), during ESPE 2026, the annual meeting of the European Society for Paediatric Endocrinology.